The risk of vertical transmission leading to chronic infection is dramatically reduced by administering hepatitis B immunoglobulin to newborns at birth together with a complete course of HBV vaccination.
H epatitis B virus (HBV) infection remains the most common form of chronic hepatitis worldwide.
The risk of vertical transmission leading to chronic infection is dramatically reduced by administering hepatitis B immunoglobulin to newborns at birth together with a complete course of HBV vaccination.
1 A high maternal HBV DNA level during pregnancy is the strongest risk factor leading to immunoprophylaxis failure (IF). 2 Because of the retrospective nature, 3 heterogeneity of the studied population, 4 and different or unknown timing of HBV DNA quantification, [3] [4] [5] the optimal HBV DNA level to identify pregnancies associated with subsequent IF remains unclear. We aimed to evaluate the risk of IF in relation to the maternal HBV DNA level at 28-30 weeks of gestation.
Methods
A prospective multicenter study was conducted from January 2014 to December 2016 at 5 hospitals in Hong Kong. All pregnant women in Hong Kong are tested for hepatitis B surface antigen (HBsAg) during their first antenatal visit. Women with a positive HBsAg status were recruited. Women receiving antiviral treatment during pregnancy were excluded. All women provided a written informed consent and were enrolled under protocols approved by the institutional review board of each hospital.
Maternal hepatitis B e antigen (HBeAg) was tested once on recruitment and the HBV DNA was quantified at 28-30 weeks using the COBAS TaqMan HBV Monitor Test (Roche Diagnostics, Branchburg, NJ) coupled with the COBAS Ampliprep extraction system (Roche Diagnostics), with a lower limit of detection of 100 copies/mL (w17.2 IU/mL) and upper limit of 990,000,000 copies/mL (w170,103,092 IU/mL; 1 IU ¼ 5.82 copies). All newborns received 10-mg HBV vaccine (Engerix-B, GlaxoSmithKline, Belgium) and 110-IU hepatitis B immunoglobulin (HyperHEP B, Grifols, Barcelona, Spain) intramuscularly at a different site within 12 hours of birth, followed by hepatitis B vaccine of same dosage at 1 and 6 months of life. HBsAg of infants was examined at 9-12 months. IF of infants (either infant in case of twin pregnancy) was defined as HBsAg positive status at 9-12 months of age.
The sample size was calculated based on comparing the proportions of IF in infants between high and low maternal predelivery HBV DNA levels. The proportions were assumed to be 2.5% and 0.01% for the groups of high and low maternal predelivery HBV DNA levels, respectively. A total of 624 subjects were required for the study with a power of 80% and a type I error of 5%. The Student t test or Wilcoxon rank sum test was used to compare quantitative variables, and the chi-square test or Fisher exact test were used to compare qualitative variables, respectively. P values < .05 were considered statistically significant. All data were analyzed with SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Data from 641 women and 654 infants (13 pairs of twins) were available for final analysis. All infants had received the hepatitis B immunoglobulin within 12 hours of birth and completed the whole course of hepatitis B vaccine on schedule. In total, 155 women (24.2%) were HBeAg positive. There were 7 cases of IF (1.1%; 7 of 641), all born to women with positive HBeAg status and HBV DNA >8 log 10 copies/mL (>17,000,000 IU/mL).
The risks of IF with HBV DNA level of <8, 8-8.99, >9 log 10 copies/mL were 0%, 8.6%, and 3.1%, respectively (Table 1) . Positive HBeAg and HBV DNA 8 log 10 copies/ mL (17,000,000 IU/mL) at 28-30 weeks were significant predictors of IF (4.5% [95% confidence interval (CI), 1.83%-9.08%] vs 0% [95% CI, 0%-0.76%], and 5.8% [95% CI, 2.36%-11.56%] vs 0% [95% CI, 0%-0.71%], respectively; P < .0001).
Discussion
Various guidelines recommend the use of antiviral therapy in women with chronic HBV and high viral load to reduce the risk of IF. 6, 7 Although a cutoff of 200,000 IU/mL (w6 log 10 copies/mL) has been recommended, 6, 7 the optimal viral load cutoff to initiate HBV antiviral treatment remains debatable. 6 The previous cutoff was derived from a retrospective observational study carried out in China 3 and a randomized controlled trial. 8 However, the information on invasive prenatal tests 3, 8 and the baseline maternal viral load of IF infants was not provided 8 in these studies. In our series, the lowest HBV DNA at which IF occurred was >8 log 10 copies/mL (>17,000,000 IU/mL), which is consistent with another prospective study, 4 after excluding 1 case with invasive prenatal test and delay first HBV vaccination. Therefore, viral load of 8 log 10 copies/mL at 28-30 weeks of gestation could be the optimal HBV DNA cutoff to predict IF. Starting antiviral treatment from 30 weeks could reduce the viral load to decrease IF. 
